Fig. 3: Protection of CoVEXS5-vaccinated hamsters against infection with divergent SARS-CoV-2 variants. | npj Vaccines

Fig. 3: Protection of CoVEXS5-vaccinated hamsters against infection with divergent SARS-CoV-2 variants.

From: An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity

Fig. 3

Hamsters were vaccinated with CoVEXS5 (5 or 20 μg) or NVX-CoV2373 (5 μg) as shown in (A), and infected with either SARS-CoV-2 Delta or XBB.1.5 at 21 days post-final vaccination. Change in body weight after challenge is shown for Delta (B) or XBB.1.5 (C) challenge. Also shown are viral loads in nasal turbinates and the lung at Day 3 post challenge (Delta, D; XBB.1.5, E). Significant differences between group were determined by two-way (B, C) or one-way (D, E) ANOVA with Tukey’s multiple comparison test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. A created with biorender.

Back to article page